Novo Nordisk exits the consolidation phase. Here are three reasons why.

Novo Nordisk's stock is drawing attention this week with its price strength, as it seems to successfully break out of the consolidation phase. Especially today, Tuesday, the stock benefits from a rotation away from AI infrastructure stocks and into more "defensive" titles. 1. Wegovy pill starts very successfully Novo Nordisk is making strides with the oral version of Wegovy launched in the U.S. in January. According to a recent report from BofA, the share of the pill in all Wegovy prescriptions rose from 33% in May to around 40% recently. The...